Market Newsdesk

CALGARY, Alberta, April 30, 2026 (GLOBE NEWSWIRE) — Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”)(NYSE American:GTE) (TSX:GTE) (LSE: GTE) announces that the Company will release its 2026 first-quarter financial and operating results on Thursday, May 7, 2026, post-market. Gran Tierra will host its first quarter 2026 results conference call on Friday, May 8, 2026, at 9:00 a.m. Mountain Time, 11:00 a.m. Eastern Time.

Gran Tierra’s 2026 Annual Meeting of Stockholders will be held on Friday, May 8, 2026, at 10:00 a.m. Mountain Time, 12:00 p.m. Eastern Time. Our Annual Meeting will be held as a virtual-only stockholder meeting with participation occurring electronically as explained further in the Proxy Statement dated March 17, 2026.

How to Participate in the Virtual Annual Meeting

Shareholders can participate electronically at https://meetings.lumiconnect.com/400-401-359-207. We recommend that you log in 15 minutes before the Annual Meeting starts. If you are a registered stockholder, to attend the Annual Meeting and vote your shares electronically and submit questions during the meeting, you will need the control number included on the Notice of Internet Availability of Proxy Materials or proxy card that accompanied your proxy materials. If you are the beneficial owner of shares held in “street name” and wish to attend the meeting, insert your name in the blank space included in the proxy form provided by your broker or other agent and submit such proxy form to your broker or other agent prior to the voting deadline to vote your shares and submit questions during the meeting. In addition, you must also register your appointment (of your broker or other agent) by emailing [email protected] no later than the voting deadline and provide Odyssey with your name, email, number of shares appointed and name of broker or other agent where shares are held, so that Odyssey may email the appointee their control number. Guests may also view the event at https://meetings.lumiconnect.com/400-401-359-207 by registering as a guest.

Full details on how to vote, change or revoke a vote, appoint a proxyholder, attend the virtual Annual Meeting, ask questions and other general proxy matters are available in the Proxy Statement available on the Company’s website at https://www.grantierra.com/events/2026-annual-meeting/.

Whether or not you plan to attend the Annual Meeting, we urge you to vote and submit your proxy in advance of the Annual Meeting by one of the methods described in the proxy materials for the Annual Meeting.

How to Participate in the 2026 First Quarter Conference Call

Interested parties may register for the 2026 first quarter conference call by clicking on this link. Please note that there is no longer a general dial-in number to participate, and each individual party must register through the provided link. Once parties have registered, they will be provided a unique PIN and call-in details. There is also a new feature that allows parties to elect to be called back through the “Call Me” function on the platform.

Interested parties can also continue to access the live webcast from their mobile or desktop devices by clicking on this link, which is also available on Gran Tierra’s website at https://www.gra ntierra.com/investor-relations/presentations-events/. An audio replay of the conference call will be available at the same webcast link two hours following the call and will be available until May 8, 2027.

Additional Information and Where to Find It

Shareholders may obtain a free copy of the proxy statement and other documents the Company files with the SEC (when available) through the website maintained by the SEC at www.sec.gov. The Company makes available free of charge on its investor relations website copies of materials it files with, or furnishes to, the SEC.

Contact Information

For investor and media inquiries please contact:

Gary Guidry
President & Chief Executive Officer

Ryan Ellson
Executive Vice President & Chief Financial Officer

+1-403-265-3221

[email protected]

About Gran Tierra Energy Inc.

Gran Tierra Energy Inc., together with its subsidiaries, is an independent international energy company currently focused on oil and natural gas exploration and production in Canada, Colombia, Ecuador. The Company is currently developing its existing portfolio of assets in Canada, Colombia and Ecuador; however, we have recently entered into an exploration, development and production sharing agreement with the State Oil Company of the Azerbaijan Republic (“SOCAR”) and may eventually expand our operations into Azerbaijan and will continue to pursue additional new growth opportunities that would further strengthen the Company’s portfolio. The Company’s common stock trades on the NYSE American, the Toronto Stock Exchange and the London Stock Exchange under the ticker symbol GTE. Additional information concerning Gran Tierra is available at www.grantierra.com. Except to the extent expressly stated otherwise, information on the Company’s website or accessible from our website or any other website is not incorporated by reference into and should not be considered part of this press release. Investor inquiries may be directed to [email protected] or (403) 265-3221.

Gran Tierra’s filings with the U.S. Securities and Exchange Commission (the “SEC”) are available on the SEC website at http://www.sec.gov. Gran Tierra’s Canadian securities regulatory filings are available on SEDAR+ at http://www.sedarplus.ca and UK regulatory filings are available on the National Storage Mechanism website at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) — Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the pricing of its initial public offering of 16,750,000 shares of its common stock at a public offering price of $18.00 per share. In addition, Hemab has granted the underwriters a 30-day option to purchase up to an additional 2,512,500 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Hemab.

Hemab’s common stock is expected to begin trading on the Nasdaq Global Select Market on Friday, May 1, 2026 under the ticker symbol “COAG.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Hemab, are expected to be approximately $301.5 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about May 4, 2026, subject to customary closing conditions.

Goldman Sachs & Co. LLC, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.

A registration statement relating to the securities being sold in the offering has been filed with the Securities and Exchange Commission and was declared effective on April 30, 2026. The offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by email at [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, by telephone at (888) 474-0200, or by email at [email protected]. 

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Hemab Therapeutics

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to the closing date of the initial public offering, the commencement of trading on the Nasdaq Global Select Market and the anticipated gross proceeds from the offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms of the offering or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus that forms a part of the effective registration statement filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Hemab’s management team and speak only as of the date hereof, and Hemab specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Media:

Deerfield
Peg Rusconi
[email protected]

Investors:

Hemab Therapeutics
Mads Behrndt
[email protected]

CHATTANOOGA, Tenn., April 30, 2026 (GLOBE NEWSWIRE) — NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or the “Company”), a leading battery materials company, today announced that it has finalized and closed the previously announced sale of its NOVONIX Battery Technology Solutions Inc. (“BTS”) business in Nova Scotia, Canada, to its former Chief Executive Officer, Dr. Chris Burns (“Buyer”).

“The divestiture of the BTS division reflects our disciplined strategy of building a vertically integrated synthetic graphite supply chain in North America,” said Mike O’Kronley, CEO of NOVONIX. “By divesting non-core business segments, we are directing our management attention and capital toward advancing domestic supply of this critical mineral and supporting the growth of the North American battery industry.”

Founded in 2013 by Dr. Chris Burns and acquired by NOVONIX in 2017, BTS will now operate as two independent companies: Avrion Battery Labs Inc., which will provide advanced battery testing systems and specialized R&D services, and Dryve Battery Materials Inc., which will continue efforts to commercialize the patented pCAM-free dry synthesis platform for lithium-ion cathode materials.

Key Deal Terms: 

• Share equity sale of the BTS business including all associated liabilities and assets
• Transaction price of US $1.00
• NOVONIX to receive a 15% equity stake in the cathode business, which will operate under Dryve Battery Materials Inc.
• Cash balance at BTS as of Close is to be US$2M, subject to agreed adjustments
• NOVONIX will provide certain transition services and will grant Buyer a trademark license through 31 December 2026

The transaction has now been successfully completed following the execution of definitive agreements and satisfaction of all closing conditions.

This announcement has been authorized for release by NOVONIX Chairman,  
Mr. Ron Edmonds.

About NOVONIX

NOVONIX strives to reduce supply chain risk, support U.S. energy independence, and establish a resilient battery materials supply chain. The company is building a North American platform for critical battery materials—anchored by its Chattanooga, Tennessee headquarters and anode materials operations, expanding through its patented all-dry, precursor-free cathode synthesis technology, and supported by industry-leading battery cell testing and R&D services.

Together, these capabilities position NOVONIX as an integrated supplier of advanced battery materials and technologies powering the energy storage and electrification economy.

To learn more, visit us at www.novonixgroup.com or on LinkedIn and X.

NOVONIX Limited

Investors: [email protected]
Media: [email protected]

Dryve Battery Materials Inc.

[email protected]

Avrion Battery Labs

[email protected]

Cautionary Note Regarding Forward-Looking Statements

This communication contains forward-looking statements about the Company and the industry in which it operates. Forward-looking statements can generally be identified by use of words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or other similar expressions. Examples of forward-looking statements in this communication include, among others, statements made regarding the anticipated benefit or impact of the BTS transaction, the advancement of the domestic supply of synthetic graphite, the growth of the North American battery industry, the future commercialization of cathode technology, and efforts to help localize the battery supply chain for critical materials and play a leading role in the transition to cleaner energy solutions.

The Company has based such statements on current expectations and projections about future events and trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. Such forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others, the timely deployment and scaling of its furnace technology, ability to meet the technical specifications and demand of existing and future customers, the accuracy of estimates regarding market size, expenses, future revenue, capital requirements, needs and access for additional financing, the availability and impact and compliance with the applicable terms of government funding and other support, ability to obtain patent rights effective to protect its technologies and processes and successfully defend any challenges to such rights and prevent others from commercializing such technologies and processes, and regulatory and economic developments in the United States, Australia, and other jurisdictions. These and other factors that could affect its business and results are included in its filings with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s most recent annual report on Form 20-F. Copies of these filings may be obtained by visiting the Company’s Investor Relations website at www.novonixgroup.com or the SEC’s website at www.sec.gov.

Forward-looking statements are not guarantees of future performance or outcomes, and actual performance and outcomes may differ materially from those made in or suggested by the forward-looking statements contained in this communication. Accordingly, you should not place undue reliance on forward-looking statements. Any forward-looking statement in this communication is based only on information currently available to us and speaks only as of the date on which it is made. The Company undertakes no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

CALGARY, Alberta, April 30, 2026 (GLOBE NEWSWIRE) — TransAlta Corporation (TSX: TA) (NYSE: TAC) (“TransAlta” or the “Company”) held its Annual and Special Meeting of Shareholders (“the Meeting”) on April 30, 2026. The total number of common shares represented by shareholders at the Meeting and by proxy was 188,939,751, representing 63.55 per cent of the Company’s outstanding common shares.

The following resolutions were considered by shareholders:

Election of Directors

The nine director nominees proposed by management were elected. The votes by ballot were received as follows:

Appointment of Auditors 

The appointment of Ernst & Young LLP to serve as the auditors for 2026 was approved. The votes by ballot were received as follows:

Advisory Vote on Executive Compensation

The non-binding advisory vote to accept the Corporation’s approach to executive compensation was approved. The votes by ballot were received as follows:

Increase in Shares Available for Issuance Under Share Unit Plan

The resolution approving the increase in the number of common shares reserved for issuance under the Corporation’s Share Unit Plan was approved. The votes by ballot were received as follows:

About TransAlta Corporation: 

TransAlta is one of Canada’s largest publicly traded power generators, delivering reliable electricity across Canada, the United States and Western Australia. For more than 100 years, our people have safely operated and evolved essential energy infrastructure that powers customers and communities. Our technology-diverse portfolio and disciplined execution allow us to deliver dependable power across evolving energy systems. We take a practical, responsible approach to meeting today’s energy needs while building for what comes next.
For more information about TransAlta, visit our web site at transalta.com. 

For more information:

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) — Kirby McInerney LLP reminds Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX) investors of the May 29, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.

If you purchased or otherwise acquired Aldeyra securities, have information, or would like to learn more, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the form below, to discuss your rights or interests.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of November 3, 2023 through March 16, 2026, inclusive (“the Class Period”). The lawsuit alleges that Aldeyra failed to disclose that (1) the results of the reproxalap (an Aldeyra drug candidate) clinical trials were inconsistent; and (2) the inconsistency of the results rendered any purported positive findings from these trials unreliable and not meaningful.

On March 17, 2026, the Company filed with the SEC a current report on Form 8-K, announcing receipt of a Complete Response Letter from the FDA, stating that there is “a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling” and that “the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.” The Complete Response Letter also stated that the “inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings” and that “the totality of evidence from the completed clinical trials does not support the effectiveness of the product.” On this news, the price of Aldeyra shares declined by $2.99 per share, or approximately 71%, from $4.23 per share on March 16, 2026 to close at $1.24 on March 17, 2026.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired Aldeyra securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[WHAT IS A SECURITIES CLASS ACTION?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP        
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
[email protected]

The Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 million in positive operating cash flow, reflecting strong resilience and consistent profitability, with a twelfth consecutive half-year of positive Adjusted EBITDA, as the Company continues to recover from the impact of the October 7, 2023 events 

NEW YORK and HERZLIYA, Israel, April 30, 2026 (GLOBE NEWSWIRE) — InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (“InterCure” or the “Company”), today announced its financial and operating results for 2025. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted.

FY2025 Financial Highlights and Milestones

^1”Adjusted EBITDA” means EBITDA for the Company’s cannabis sector, adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, and other expenses (or income). Other income, net includes war-related damage compensation from the tax authorities, changes to allowance for credit risk, impairment of inventory and excludes non-cannabis sector expenses. EBITDA means net income (loss) before interest, taxes, depreciation and amortization.
^2” Including restricted cash

Operational and Strategic Highlights


  

Alexander Rabinovitch, CEO and Chairman of InterCure,:

“We believe that 2025 marked a year of disciplined execution and accelerating recovery for InterCure, and that we delivered strong momentum in the second half of the year, with nearly 20% revenue growth, while maintaining positive Adjusted EBITDA for the twelfth consecutive half-year. Importantly, we generated NIS 17 million in positive operating cash flow, supporting debt repayment and strengthening the Company’s financial position.

During the year, we achieved a significant operational milestone by resuming production at our Nir Oz facility and delivering our first batches since the October 7, 2023 events. At the same time, we launched a record number of new products, which we believe reinforces our leadership in the premium medical cannabis category.

The rehabilitation of the Nir Oz site is extending beyond the originally planned timeline and remains a complex, resource-intensive process, progressing in line with the receipt of additional compensation advances.

We also achieved a key milestone with our first meaningful revenues in the German market, supporting the continued execution of our global expansion strategy across Germany and additional markets throughout 2026. The anticipated launch of operations under the Botanico transaction, together with our strategic collaboration with Cannasoul, is expected to further enhance our pharmaceutical platform and global positioning.

In parallel, we are closely monitoring regulatory developments, including recent statements from U.S. authorities recognizing the medical value of cannabis. We believe that these developments, alongside evolving frameworks in the United States and Europe, further support our strategic positioning to leverage our vertically integrated model, scientific leadership, and international partnerships to drive long-term value for patients and shareholders.”

Company’s Revenues and Adjusted EBITDA 2022-2025

(*) Results were affected by damages to our southern facility caused by the terrorist attack on October 7, 2023, and the war in Gaza.

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (NASDAQ: INCR) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: https://www.intercure.co

³ The claim is not final and remains subject to adjustment. The total amount claimed may be increased as the recovery process is being extended in line with the receipt of additional compensation advances and further information becomes available.

Non-IFRS Measures

This press release makes reference to certain non-IFRS financial measures. Adjusted EBITDA, as defined by InterCure, means earnings before interest, income taxes, depreciation, and amortization, adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, and other income, net which included war-related damage compensation from the tax authorities, changes to allowance for credit risk, and impairment of inventory. This measure is not a recognized measure under IFRS, does not have a standardized meaning prescribed by IFRS and is therefore unlikely to be comparable to similar measures presented by other companies. InterCure’s method of calculating this measure may differ from methods used by other entities and accordingly, this measure may not be comparable to similarly titled measures used by other entities or in other jurisdictions. InterCure uses this measure because it believes it provides useful information to both management and investors with respect to the operating and financial performance of the Company.

Below is a table of reconciliation of Adjusted EBITDA to net income:

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements may include, but are not limited to, the Company’s resilience and consistent profitability, the Company’s expected recovery from the impact of the October 7, 2023 events, the Company’s expected growth, including in Adjusted EBITDA, the Company’s and its subsidiaries continued expansion, the Company’s partnerships, investments, collaborations and strategy, the Company’s financial results, regulatory developments, legal proceedings, and expected receipt of compensation from the Israeli government, as well as statements, other than historical facts, that address activities, events or developments that InterCure intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause InterCure’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company’s resilience, profitability and financial position; the Company’s recovery from the October 7, 2023 events and resumed production, importations and sales from the Nir Oz facility; the Company’s leadership in the premium medical cannabis categorty, the Company’s financial result and projections, including in different markets; the Company’s success with its partenrships, the Company’s success in executing its global expansion plans (including the pending acquisition of Botanico Ltd. (ISHI) and its closing); the ability to satisfy the conditions to closing and complete the ISHI Acquisition Agreement; the Company’s expectation to launch operations under the Botanico transaction; the Company’s expectation to enhance its pharmaceutical platform and global positioning; the Company’s expectations regarding expansion, product launches and revenues in 2026 and in the future; the increase of the Company’s holdings in Cannasoul R&D Ltd. and its expectation that his partnership will enhance the Company’s capabilities and support its positioning; regulatory developments in the United States, including potential rescheduling of cannabis, and benefits from such developments; the proceedings initiated by Bazelet and its results and the Company’s expectation to drive long-term value for patients and shareholders; its continued growth, expected operations and financial results, business strategy, competitive strengths, goals and expansion into major markets worldwide; the impact of the ongoing conflict in Israel and regional geopolitical conditions, the Company’s ability to obtain additional compensation from Israeli authorities, . Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, the U.S. regulatory landscape and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, and reliance on the expertise and judgment of our senior management. More detailed information about the risks and uncertainties affecting us is contained under the heading “Risk Factors” included in the Company’s most recent Annual Report on Form 20-F, as well as in the Company’s Report of Foreign Private Issuer on Form 6-K containing the unaudited condensed consolidated financial statements for the six months ended June 30, 2025, and in other filings that we have made and may make with the Securities and Exchange Commission in the future.

Company Contact:

InterCure Ltd.
Amos Cohen, Chief Financial Officer
[email protected] 

THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) — Ring Energy, Inc. (NYSE American: REI) (“Ring” or the “Company”) today announced the timing of its first quarter 2026 earnings release and conference call.

Ring plans to issue its first quarter 2026 earnings release after the close of trading on Wednesday, May 6, 2026. The Company has scheduled a conference call on Thursday, May 7, 2026 at 11:00 a.m. ET (10:00 a.m. CT) to discuss its first quarter 2026 operational and financial results. To participate, interested parties should dial 833-953-2433 at least five minutes before the call is to begin. Please reference the “Ring Energy Earnings Conference Call”. International callers may participate by dialing 412-317-5762. The call will also be webcast and available on Ring’s website at www.ringenergy.com under “Investors” on the “News & Events” page. An audio replay will also be available on the Company’s website following the call.

About Ring Energy, Inc.

Ring Energy, Inc. is an oil and gas exploration, development, and production company with current operations focused on the development of its Permian Basin assets. For additional information, please visit www.ringenergy.com.

Contact Information

Al Petrie Advisors
Al Petrie, Senior Partner
Phone: 281-975-2146
Email: [email protected]